Tadalafil (Generic) and Diphenhydramine Interaction: What You Need to Know

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor sold under the brand name Cialis and as generic tadalafil tablets, FDA-approved for erectile dysfunction (10-20 mg on demand or 2.5-5 mg daily) and for benign prostatic hyperplasia (BPH, 5 mg daily). Diphenhydramine is a first-generation antihistamine, sold over the counter as Benadryl, ZzzQuil, and in Unisom SleepTabs, used for allergy symptoms and as a sleep aid.

Tadalafil and diphenhydramine do not interact at the level of drug metabolism. Diphenhydramine does not meaningfully inhibit the CYP3A4 enzyme that clears tadalafil, so co-administration is not expected to raise tadalafil blood levels. The concern is pharmacodynamic: diphenhydramine's sedating and anticholinergic effects can add to tadalafil's own tendency to lower blood pressure and cause dizziness, and this overlap is more consequential in adults over 65, in anyone with BPH, and in people taking blood pressure medication. Most drug-interaction references classify the combination as low to moderate, not a contraindication, but several major reference sources and formal trial data specific to this exact combination are lacking, so the guidance below rests partly on pharmacological reasoning rather than a dedicated interaction study.

How the two drugs work, and where their effects overlap

What tadalafil does

By blocking PDE5, tadalafil slows the breakdown of cyclic GMP, which sustains smooth-muscle relaxation in penile blood vessels and, at the BPH-approved 5 mg dose, in the bladder neck and prostate. This relaxation lowers vascular resistance and can produce a mild reduction in blood pressure, an effect documented in tadalafil's FDA prescribing information. Tadalafil is cleared mainly through hepatic CYP3A4 metabolism, and its half-life of roughly 17.5 hours is notably longer than sildenafil or vardenafil, meaning a dose taken on one day can still be pharmacologically active more than a full day later.

What diphenhydramine does

Diphenhydramine is a first-generation H1 antihistamine that crosses into the brain readily, producing sedation, and it also blocks muscarinic (anticholinergic) receptors throughout the body. That anticholinergic action is responsible for dry mouth, constipation, and, importantly for men with an enlarged prostate, reduced bladder contraction that can worsen urinary retention. Diphenhydramine is metabolized mainly by CYP2D6, with a lesser CYP3A4 contribution, but at the doses used in OTC allergy and sleep products it is not considered a clinically meaningful inhibitor of CYP3A4.

Why this matters together

Because diphenhydramine does not meaningfully block the enzyme that clears tadalafil, tadalafil blood levels are not expected to rise when the two are combined. The interaction instead comes from two separate effects landing on the same patient at the same time: tadalafil's vasodilation and diphenhydramine's sedation and anticholinergic load can each independently contribute to dizziness, drowsiness, and (in susceptible patients) a drop in blood pressure on standing. In men taking tadalafil for BPH, diphenhydramine's anticholinergic effect on the bladder can worsen urinary symptoms regardless of blood pressure.

How serious is this, and for whom?

The combination is not listed as contraindicated by tadalafil's FDA labeling, and it is not one of the drug classes (nitrates, certain alpha-blockers in specific dosing sequences) that carry an explicit warning on the label. Interaction severity in this case scales with a handful of identifiable factors:

• Tadalafil dose: higher acute risk with 20 mg taken on demand than with 2.5-5 mg daily dosing, because peak drug concentration and peak hemodynamic effect are higher.
• Age: anticholinergic sensitivity, fall risk, and confusion risk from diphenhydramine rise substantially in adults over 65.
• Baseline blood pressure: patients who already run on the lower end of normal blood pressure have less buffer against an additive drop.
• Concurrent antihypertensive medication: alpha-blockers, calcium channel blockers, and ACE inhibitors add a third pharmacodynamic layer.
• Diphenhydramine dose: a single 25 mg allergy dose carries a different risk profile than a nightly 50 mg sleep-aid dose.

General adult population

A healthy adult under 60 taking tadalafil 5 mg daily for BPH or 10 mg on demand for erectile dysfunction who takes a single 25 mg diphenhydramine tablet for allergy symptoms faces a low practical risk of a clinically important event. Mild dizziness is possible; fainting is uncommon and typically requires additional risk factors to be present.

Older adults

This is the group requiring the most caution. Diphenhydramine is widely flagged by geriatric prescribing guidance as a drug to generally avoid in adults 65 and older because of its anticholinergic burden, its association with falls, and its potential to cause acute confusion. Tadalafil independently raises fall risk through orthostatic blood pressure drops. Recommending or continuing both together in a patient over 65 deserves a documented discussion of the tradeoffs, and a non-anticholinergic alternative should generally be considered first. (Readers should verify current guidance directly against the most recent American Geriatrics Society Beers Criteria publication rather than relying on a summary, since criteria are periodically updated.)

Men with BPH

This deserves specific emphasis because the risk here is largely independent of blood pressure. Diphenhydramine's anticholinergic action reduces bladder detrusor muscle contraction. A man taking tadalafil 5 mg daily for lower urinary tract symptoms who also takes diphenhydramine 50 mg at bedtime, a common OTC sleep-aid dose, may develop worsened urinary hesitancy or, less commonly, acute urinary retention. This is a mechanistically plausible and clinically recognized risk of diphenhydramine in men with prostate enlargement generally, separate from any tadalafil-specific mechanism.

Pharmacokinetic profile, side by side

The key takeaway from this comparison is timing: because tadalafil's half-life is so long, a patient who takes tadalafil 20 mg one evening and then diphenhydramine the following night is not starting from a clean slate. Meaningful tadalafil exposure persists well beyond same-day co-ingestion, so "avoid taking them at the same time" is not a reliable safety strategy on its own.

What to monitor, and when to seek care

Blood pressure. Anyone with cardiovascular risk factors who combines these drugs should check blood pressure, ideally 60-90 minutes after dosing when both drugs are near peak effect. A systolic reading under 90 mmHg, or a drop of more than 20 mmHg from baseline, is a reason to hold the diphenhydramine dose and contact a clinician.

Dizziness on standing. New dizziness when rising from sitting or lying down should be reported. A simple check is to measure blood pressure lying down, then again after standing for about a minute; a systolic drop of more than 20 mmHg or a diastolic drop of more than 10 mmHg is generally used to define orthostatic hypotension in clinical practice, and warrants follow-up.

Urinary symptoms in men with BPH. Difficulty starting urination, a weak stream, or inability to void are red-flag symptoms that call for same-day contact with a clinician, not a wait-and-see approach.

Sedation and driving. Diphenhydramine alone already carries a caution against driving or operating machinery for several hours after dosing. When combined with tadalafil-related dizziness, that caution should extend for as long as any lightheadedness persists.

Seek emergency care for any loss of consciousness, chest pain or pressure, inability to urinate for several hours despite feeling the urge, or sudden severe headache or vision change after taking both drugs. These symptoms are not typical of either drug alone and should prompt evaluation to rule out significant hypotension or urinary retention needing catheterization.

Dose considerations

No formal, dedicated dose adjustment of tadalafil is established specifically because of diphenhydramine co-administration, since there is no known pharmacokinetic interaction driving one. That does not mean no adjustment in behavior is warranted; it means the adjustment is about timing and monitoring rather than milligram changes.

Evidence-status assessment: tadalafil + diphenhydramine

Established (supported by product labeling or well-characterized pharmacology of each drug):

• Tadalafil is metabolized by hepatic CYP3A4 and has a long half-life (roughly 17.5 hours), documented in its FDA prescribing information.
• Diphenhydramine has strong anticholinergic and CNS-sedating activity, well documented across pharmacology references, and is not a clinically meaningful CYP3A4 inhibitor at OTC doses.
• Tadalafil can lower blood pressure and is explicitly labeled with cautions around drugs and substances (alcohol, nitrates, certain antihypertensive sequencing) that add to that effect.
• Diphenhydramine's anticholinergic action can impair bladder emptying, a mechanism relevant to any man with BPH regardless of concurrent PDE5 inhibitor use.

Plausible but not directly proven by a dedicated study of this pair:

• That the combination measurably increases symptomatic hypotension or fall risk beyond what either drug produces alone, in a dose-dependent way, has biological plausibility but has not been confirmed by a controlled pharmacodynamic trial identified for this article.
• That timing diphenhydramine away from tadalafil's peak effect meaningfully reduces risk is a reasonable extrapolation from half-life data, not a tested clinical strategy.

Not established:

• No FDA safety communication or label update specifically addresses the tadalafil-diphenhydramine combination.
• No published randomized or prospective study measuring blood pressure, fall incidence, or urinary retention specifically in patients taking both drugs together was identified for this article. Interaction database classifications (Lexicomp, Micromedex, and similar tools) should be checked directly for their current wording and evidence grading, since these are not reproduced here.

What a clinician or pharmacist should verify before individualized counseling:

• Current interaction-severity classification in an up-to-date drug interaction database, since classifications are revised over time.
• The patient's specific tadalafil dose, indication (ED versus BPH), and any concurrent antihypertensive or alpha-blocker therapy.
• The patient's age and any existing anticholinergic medication burden, since diphenhydramine adds to a cumulative anticholinergic load from other drugs.
• Baseline blood pressure and any history of orthostatic symptoms or falls.

Alternatives worth discussing

When a patient on tadalafil needs an antihistamine or a sleep aid, options with less anticholinergic and sedative overlap include:

• For allergies: cetirizine or loratadine, second-generation antihistamines with minimal anticholinergic activity and no established significant interaction with PDE5 inhibitors; fexofenadine is another low-sedation option.
• For sleep: melatonin, which does not share tadalafil's cardiovascular pharmacodynamic profile; cognitive behavioral therapy for insomnia is recommended as a first-line, non-pharmacologic option for chronic insomnia by major clinical practice guidelines, and carries no drug interaction risk at all. Doxylamine, another first-generation antihistamine sold as a sleep aid, shares diphenhydramine's anticholinergic concerns and is not a meaningfully safer substitute.

Special populations

Kidney impairment. Tadalafil accumulates when kidney function is reduced, and its FDA label specifies lower maximum doses at reduced creatinine clearance. Diphenhydramine's metabolites can also accumulate in renal impairment. Combining the two in a patient with significant chronic kidney disease calls for closer blood pressure and urinary monitoring, and dosing should follow the current FDA label rather than general guidance.

Liver impairment. Tadalafil is not recommended in severe hepatic impairment. Diphenhydramine clearance is prolonged in liver disease, which extends both its sedative and anticholinergic effects. Neither drug should be used in significant liver disease without a clinician's review of the specific case.

Cardiovascular disease. Tadalafil is contraindicated with nitrate medications because of a risk of severe hypotension; this is unrelated to diphenhydramine specifically. Patients with cardiovascular disease who have been cleared for sexual activity by their treating physician should still discuss any addition of diphenhydramine with that physician, since it introduces an additional, if generally modest, hemodynamic variable.

What the evidence does not yet show

No prospective study measuring blood pressure or fall outcomes specifically in patients taking tadalafil and diphenhydramine together was identified in the sources reviewed for this article. Interaction guidance for this pair is derived from the separately well-documented pharmacology of each drug rather than from a dedicated trial or a specific FDA safety communication. That is a common situation across many drug pairs that have never been formally studied together, and it does not make the concern hypothetical: the anticholinergic and sedative effects of diphenhydramine and the hypotensive potential of tadalafil are each independently well established, and their overlap is physiologically coherent. Readers and clinicians should treat the risk stratification above as reasoned pharmacological guidance, and verify current interaction-severity ratings against an up-to-date pharmacy reference before making individualized decisions.

This article summarizes general drug-interaction pharmacology and is not individualized medical advice. It is pending qualified clinical review before publication. Anyone taking both medications, especially adults over 65, people with BPH, or anyone on blood pressure medication, should confirm specific guidance with a pharmacist or prescribing clinician.